Abstract:Overcoming the FLT3-ITD mutant has been a promising drug design strategy for treating acute myeloid leukemia (AML). Herein, we discovered a novel FLT3 inhibitor 17, which displayed potent inhibitory activity against the FLT3-ITD mutant (IC50 = 0.8 nM) and achieved good selectivity over c-KIT kinase (over 500-fold). Compound 17 selectively inhibited the proliferation of FLT3-ITD-positive AML cell lines MV4-11 (IC50 = 23.5 nM) and MOLM-13 (IC50 = 35.5 nM) and exhibited potent inhibitory effects against associated acquired resistance mutations. In cellular mechanism studies, compound 17 strongly inhibited FLT3-mediated signaling pathways and induced apoptosis by arresting the cell cycle in the sub-G1 phase. In in vivo studies, compound 17 demonstrated a good bioavailability (73.6%) and significantly suppressed tumor growth in MV4-11 (10 mg/kg, TGI 93.4%) and MOLM-13 (20 mg/kg, TGI 98.0%) xenograft models without exhibiting obvious toxicity. These results suggested that compound 17 may be a promising drug candidate for treating FLT3-ITD-positive AML.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c02247?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02247</a>.KINOME scan selectivity profiling data of compound 17; NMR spectra of all target compounds; HPLC spectra of representative compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02247/suppl_file/jm0c02247_si_001.pdf">PDF</a>)Molecular formula strings and some data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02247/suppl_file/jm0c02247_si_002.csv">CSV</a>)Molecular docking information on compound 17 to FLT3 homology model <a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02247/suppl_file/jm0c02247_si_003.pdb">PDB</a>Molecular docking information on compound 17 to FLT3 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02247/suppl_file/jm0c02247_si_004.pdb">PDB</a>)Molecular docking information on compound 1 to FLT3 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02247/suppl_file/jm0c02247_si_005.pdb">PDB</a>)Molecular docking information on compound 17 to c-KIT (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02247/suppl_file/jm0c02247_si_006.pdb">PDB</a>)Molecular docking information on sunitinib to c-KIT (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02247/suppl_file/jm0c02247_si_007.pdb">PDB</a>)Crystal structure of c-KIT kinase domain in complex with imatinib (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02247/suppl_file/jm0c02247_si_008.pdb">PDB</a>)This article has not yet been cited by other publications.

Discovery of N-((1-(4-(3-(3-((6,7-Dimethoxyquinolin-3-yl)oxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)methyl)propionamide (CHMFL-KIT-8140) as a Highly Potent Type II Inhibitor Capable of Inhibiting the T670I “Gatekeeper” Mutant of cKIT Kinase

Discovery of (E)-N1-(3-fluorophenyl)-n3-(3-(2-(pyridin-2-yl)vinyl)-1h-indazol-6-yl)malonamide (CHMFL-KIT-033) As a Novel C-Kit T670I Mutant Selective Kinase Inhibitor for Gastrointestinal Stromal Tumors (Gists)

Discovery of 2-(4-chloro-3-(trifluoromethyl)phenyl)-n-(4-((6,7-dimethoxyquinolin-4-yl )oxy)phenyl)acetamide (CHMFL-KIT-64) As a Novel Orally Available Potent Inhibitor Against Broad Spectrum Mutants of C-Kit Kinase for Gastrointestinal Stromal Tumors

Discovery of N-(3-((1-Isonicotinoylpiperidin-4-yl)oxy)-4-methylphenyl)-3-(trifluoromethyl)benzamide (CHMFL-KIT-110) As a Selective, Potent, and Orally Available Type II C-Kit Kinase Inhibitor for Gastrointestinal Stromal Tumors (Gists)

Discovery of a highly selective KIT kinase primary V559D mutant inhibitor for gastrointestinal stromal tumors (GISTs).

Discovery of 4-Methyl-n-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((1-nicotinoylpiperidin-4-yl)oxy)benzamide (CHMFL-ABL/KIT-155) As a Novel Highly Potent Type II ABL/KIT Dual Kinase Inhibitor with a Distinct Hinge Binding

Discovery of 2-Aminopyrimidine Derivatives As Potent Dual FLT3/CHK1 Inhibitors with Significantly Reduced Herg Inhibitory Activities.

Discovery of Potent, Selective Stem Cell Factor Receptor/Platelet Derived Growth Factor Receptor Alpha (C-Kit/pdgfrα) Dual Inhibitor for the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors (Gists).

Discovery of 5-trifluoromethyl-2-aminopyrimidine derivatives as potent dual inhibitors of FLT3 and CHK1

Discovery of a Potent and Selective FLT3 Inhibitor ( Z )- N -(5-((5-Fluoro-2-oxoindolin-3-ylidene)methyl)-4-methyl-1 H -pyrrol-3-yl)-3-(pyrrolidin-1-yl)propanamide with Improved Drug-like Properties and Superior Efficacy in FLT3-ITD-Positive Acute Myeloid Leukemia

Discovery of (R)-5-((5-(1-methyl-1h-pyrazol-4-yl)-4-(methylamino)pyrimidin-2-yl)amino)-3-(piperidin-3-yloxy)picolinonitrile, a Novel CHK1 Inhibitor for Hematologic Malignancies.

Discovery of 1-{(3R,4R)-3-[5-Chloro-2-(1-methyl-1H-pyrazol-4-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxymethyl]-4-methoxy-pyrrolidin-1-yl}propenone (PF-06459988), A Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants.

A new monoclonal antibody that blocks dimerisation and inhibits c-kit mutation-driven tumour growth

Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant gastrointestinal stromal tumors

Discovery And Characterization Of A Novel Irreversible Egfr Mutants Selective And Potent Kinase Inhibitor Chmfl-Egfr-26 With A Distinct Binding Mode

Co-targeting of ACK1 and KIT triggers additive anti-proliferative and -migration effects in imatinib-resistant gastrointestinal stromal tumors

Discovery of (R)-1-(3-(4-amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) As a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode.

Axitinib Overcomes Multiple Imatinib Resistant Ckit Mutations Including the Gatekeeper Mutation T670I in Gastrointestinal Stromal Tumors

Repurposing Cabozantinib to GISTs: Overcoming Multiple Imatinib-Resistant Ckit Mutations Including Gatekeeper and Activation Loop Mutants in GISTs Preclinical Models.

Molecular Modeling Study of c-KIT/PDGFRα Dual Inhibitors for the Treatment of Gastrointestinal Stromal Tumors

Discovery of (E)-N-(4-methyl-5-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thiazol-2-yl)-2-(4-methylpiperazin-1-yl)acetamide (IHMT-TRK-284) as a novel orally available type II TRK kinase inhibitor capable of overcoming multiple resistant mutants